A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin™

Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease

“…The synthesis, characterization, and purification of the bifunctional ligand TCMC has been previously described (27,28). Trastuzumab was conjugated with TCMC by established methods using a 10-fold molar excess of ligand to mAb (29). The protein concentration was quantified by the method of Lowry (30).…”

“…Immunoreactivities of the radiolabeled preparations were assessed in a RIA as detailed previously using SKOV-3 (29). SKOV-3 cells express HER2 at f5 Â 10 5 receptors per cell (32).…”

Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule

“…A monoclonal antibody directed against HER2 (trastuzumab) is a registered therapeutic for breast cancer (15), and a number of small-molecule kinase inhibitors (16) and vaccine strategies (17) are in clinical development. HER2 is also considered as a promising target for radionuclide therapy of, for example, breast cancer (18), and both HER2-recognizing antibodies and their fragments have been evaluated in this context (19)(20)(21)(22)(23).…”

“…To assess the influence of radionuclide therapy using 177 Lu-CHX-A 00 -DTPA-ABD-(Z HER2:342 ) 2 on xenografts derived from cells with low level of HER2 expression, a colorectal carcinoma cell line LS174T was used (20,36 Lu-CHX-A 00 -DTPA-ABD-(Z HER2:342 ) 2 (n = 9), 22.3 MBq of non-HER2-specific 177 Lu-CHX-A 00 -DTPA-ABD-(Z abeta ) 2 (n = 8, control), or PBS (n = 9). The presence and size of tumors were assessed as described above, and animals were euthanized if tumors were larger than 1 mL or were ulcerated.…”

Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site

“…In-mAb might not accurately predict the dosimetry of 90 Y-mAb because it has been reported that 111 In-mAb did not parallel the uptake of 86 Y-mAb in bone [5].…”